Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327:681-682 (20 September), doi:10.1136/bmj.327.7416.681-c
| The first 150 words of the full text of this article appear below. |
EDITORThe conundrum of the HOPE (heart outcomes prevention evaluation) study is resolved.1 Why was there no relation between blood pressure and outcome? Answer: Because ramipril was taken at bedtime.
Separate papers in the BMJ and Lancet reported that risk reduction for stroke and cardiovascular end points in the HOPE study were much greater than could be accounted for by the small reduction in measured blood pressure.2 3 Both papers suggested that ramipril had brought about a specific beneficial effect unrelated to blood pressure lowering. However, neither paper mentioned when the ACE inhibitor dose was taken in relation to blood pressure measurement.
A previous report by an overlapping authorship reported that HOPE "is the only large trial in which an antihypertensive agent, according to the study protocol, has been recommended to be given at bedtime" and that blood pressure was measured on the following day, between 12 and 18 hours
Roy Taylor, professor of medicine and metabolism
University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH roy.taylor@ncl.ac.uk
Read all Rapid Responses